RAFAEL VALVERDE Rafael lives with obesity Mexico Novo Nordisk – a focused healthcare company Investor presentation First nine months of 2025 2 Novo Nordisk® Investor presentation First nine months of 2025 Agenda Progress on Strategic Aspirations 2025 Financials Innovation and therapeutic focus Commercial execution Agenda 3 Novo Nordisk® Investor presentation First nine months of 2025 Forward-looking statements Novo Nordisk's statutory Annual Report 2024, Form 20-F, any quarterly financial reports, investor ...

RAFAEL VALVERDE Rafael lives with obesity Mexico Novo Nordisk – a focused healthcare company Novo Nordisk to acquire Akero Therapeutics Inc. 2 Investor presentation 9 October 2025 Forward-looking statements Novo Nordisk's statutory Annual Report 2024, Form 20-F, any quarterly financial reports, investor presentations and written information released, shown, or oral statements made, to the public in the future by or on behalf of Novo Nordisk, may contain certain forward-looking statements relating to the ope ...

Core Insights - Berger Montague PC is investigating claims against Novo Nordisk A/S under federal securities laws following a class action lawsuit filed against the company [1][2]. Company Performance - On July 29, 2025, Novo Nordisk lowered its sales and profit guidance for the second half of fiscal 2025, attributing this to persistent use of compounded GLP-1s, slower-than-expected market expansion, and increased competition for its products Wegovy® and Ozempic® [3]. - Following the announcement, Novo's stock price fell from $69.00 to $53.94 per share, marking a one-day decline of over 21% [3]. Investor Information - Investors who purchased or acquired Novo securities between May 7, 2025, and July 28, 2025, have until September 30, 2025, to seek appointment as lead plaintiff representative of the class [2].

Core Viewpoint - A class action lawsuit has been filed against Novo Nordisk A/S by Berger Montague PC on behalf of investors who acquired Novo's publicly traded securities during the specified class period from May 7, 2025, to July 28, 2025 [1][2] Company Summary - Novo Nordisk A/S is a global pharmaceutical company headquartered in Denmark [3] - The lawsuit alleges that Novo understated the impact of the personalization exception to the compounded GLP-1 exclusion, which has allowed continued use of compounded alternatives to its products [3] - The company is accused of overstating the likelihood that patients using less expensive compounded drugs would switch to its branded products, leading to an overestimation of its long-term growth potential [3] Financial Impact - On July 29, 2025, Novo announced a reduction in its sales and profit outlook for fiscal 2025, citing slower-than-expected growth for its products Wegovy® and Ozempic® due to competition from compounded GLP-1 products [4] - Following this announcement, Novo's stock price fell from $69.00 per share on July 28, 2025, to $53.94 per share on July 29, representing a decline of approximately 21.83% in a single day [4]

Accessibility StatementSkip Navigation 440k+Newsrooms &Influencers 9k+Digital MediaOutlets 270k+JournalistsOpted In GET STARTED PHILADELPHIA, Sept. 22, 2025 /PRNewswire/ -- Berger Montague PC is investigating potential securities fraud claims on behalf of investors of Novo Nordisk A/S. (NYSE: NVO) ("Novo" or the "Company") following the filing of a securities class action lawsuit. The lawsuit was filed on behalf of investors who purchased or otherwise acquired Novo securities from May 7, 2025 through ...

Core Insights - Novo Nordisk is set to present 35 abstracts related to its diabetes and obesity portfolio at the EASD congress 2025, highlighting the health benefits and weight loss effects of semaglutide, along with new obesity pipeline therapies [1][3][4] Company Developments - The company will host an R&D investor event on 17 September to discuss the science and abstracts presented at the congress, which will be available via live webcast [2] - Semaglutide is recognized for having the broadest approved indications for obesity and type 2 diabetes, contributing to weight loss and cardiovascular protection [3] Research Presentations - Key presentations include the SOUL trial on oral semaglutide's cardiovascular outcomes, and various studies on the effectiveness of semaglutide and its impact on eating behaviors and body composition [5][7][8] - The REDEFINE trials will present data on the efficacy of cagrilintide and amycretin as next-generation obesity treatments [11][17] Product Information - Semaglutide is marketed under the brand names Wegovy® (2.4 mg injection), Ozempic® (1.0 mg injection), and Rybelsus® (14 mg oral) [14] - The drug has a well-established safety profile supported by over 33 million patient-years of exposure since its launch in 2018 [13]

Core Viewpoint - Berger Montague PC is investigating potential securities fraud claims against Novo Nordisk A/S following a securities class action lawsuit filed on behalf of investors who acquired Novo securities during the Class Period from May 7, 2025, to July 28, 2025 [1][3] Group 1 - The lawsuit alleges that Novo Nordisk made false and misleading statements regarding the impact of compounded GLP-1 drugs, specifically underestimating the effect of the FDA's personalization exception [3] - The company allegedly overstated the likelihood that patients would switch to its branded drugs, such as Ozempic® and Wegovy®, leading to significant investor losses [3] - Investors who purchased Novo securities during the Class Period have until September 30, 2025, to seek appointment as lead plaintiff representative of the class [2]

Core Insights - Novo Nordisk announced new data on the cardiovascular protective benefits of Wegovy® and Ozempic® to be presented at the ESC Congress 2025, highlighting the role of inflammation in atherosclerotic cardiovascular disease (ASCVD) [1][3] Group 1: Cardiovascular Benefits - Semaglutide has been shown to reduce the risk of cardiovascular events by 20-26%, leading to fewer hospitalizations, heart attacks, strokes, and deaths for individuals with diabetes and obesity [2] - The unique benefits of semaglutide on heart and kidney disease will be substantiated through both clinical trials and real-world evidence at the ESC Congress [4] Group 2: Scientific Presentations - Key presentations will include data on Ozempic® (1.0 mg), Rybelsus® (oral semaglutide), and Wegovy® (2.4 mg), focusing on their impact on conditions like atrial fibrillation and cardiometabolic benefits in type 2 diabetes [5][6] - Specific sessions will address the effects of semaglutide on heart failure outcomes, cardiovascular risk factors, and the relationship between inflammation and cardiovascular events [6][13] Group 3: Research and Evidence - Real-world evidence will be presented to analyze the impact of inflammation on mortality and major cardiovascular events in individuals with ASCVD [3][5] - The role of systemic inflammation in cardiovascular disease and chronic kidney disease will be explored through various studies and analyses during the congress [13][19]

Core Viewpoint - Berger Montague PC is investigating claims against Novo Nordisk A/S following a class action lawsuit related to the company's lowered sales and profit guidance for the second half of fiscal 2025 [1][3]. Company Summary - Novo Nordisk A/S, a global pharmaceutical company based in Denmark, has faced a significant stock price decline after announcing a reduction in sales and profit expectations due to various market challenges [1][3]. - The company cited persistent use of compounded GLP-1s, slower-than-expected market expansion, and increased competition for its products Wegovy® and Ozempic® as reasons for the guidance cut [3]. Stock Performance - Following the announcement on July 29, 2025, Novo's stock price fell from $69.00 to $53.94 per share, marking a one-day decline of over 21% [3]. Investor Information - Investors who purchased Novo securities between May 7, 2025, and July 28, 2025, have until September 30, 2025, to seek appointment as lead plaintiff representative in the class action [2].

Core Viewpoint - Berger Montague PC is investigating claims against Novo Nordisk A/S following a class action lawsuit related to the company's lowered sales and profit guidance for the second half of fiscal 2025 [1][3]. Group 1: Company Performance - On July 29, 2025, Novo Nordisk lowered its sales and profit guidance for the second half of fiscal 2025, attributing this to persistent use of compounded GLP-1s, slower-than-expected market expansion, and increased competition for its products Wegovy® and Ozempic® [3]. - Following the announcement, Novo's stock price fell from $69.00 to $53.94 per share, marking a one-day decline of over 21% [3]. Group 2: Legal Actions - A class action lawsuit has been filed against Novo Nordisk, and investors who purchased or acquired Novo securities between May 7, 2025, and July 28, 2025, may seek to be appointed as lead plaintiff representatives by September 30, 2025 [2].